Latest News

FDA fast-tracks off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

A B7-H3–targeted antibody-drug conjugate showed benefit vs chemotherapy in relapsed osteosarcoma.

Digital app-based therapy helps breast cancer survivors cut anxiety over 12 months, while depression gains lag; coaching boosts early use.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

Phase 3 results show intravesical cretostimogene drives durable complete responses and bladder preservation in BCG-unresponsive NMIBC.

FDA fast-tracks ISM6331 for hard-to-treat pleural mesothelioma, spotlighting Hippo pathway targeting and early phase 1 results presented at ESMO 2026.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is to determine whether data from the IGNYTE trial can support an accelerated approval of RP1 plus nivolumab.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

In an interview, Brian C. Betts, MD, revealed how Roswell Park Comprehensive Cancer Center achieved a dramatic increase in patient survival after allogeneic hematopoietic cell transplant.

Monthly IVIG prophylaxis sharply lowers moderate infections in CLL with low IgG, suggesting better quality of life despite baseline Ig levels.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.

Sonesitatug vedotin boosted overall survival vs chemotherapy in second-line and later CLDN18.2-positive gastric/GEJ cancers.

FIT-001 updates show darlifarnib plus cabozantinib drives 33% to 50% responses and 13‑month PFS in pretreated patients with cabozantinib-naive ccRCC.

Dr Erica Stringer-Reasor of UAB discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

Results of a retrospective study suggest that response to immune checkpoint inhibitors in sarcoma may be linked to other factors besides level of tumor mutational burden or mismatch repair deficiency.

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

An oral combination of sirolimus and domatinostat is being used to treat patients with metastatic osteosarcoma and other sarcomas.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks drinking habits.

The MonumenTAL-6 study found significant improvement with the combination of teclistamab and talquetamab vs standard regimens in relapsed/refractory multiple myeloma.

The ProstACT SELECT trial demonstrated safety and antitumor activity for TLX591-Tx in a population selected by PSMA expression in metastatic castration-resistant prostate cancer.

The FDA will review the PARP inhibitor/androgen pathway receptor inhibitor combination in metastatic castration-sensitive prostate cancer in the fourth quarter of 2026.

Early phase 2 data show IMNN-001 added to chemo plus bevacizumab reduces residual ovarian cancer, boosts ctDNA clearance, and remains well tolerated.

Longer follow-up links ivonescimab plus chemo to stronger survival gains in EGFR-mutant NSCLC worldwide, supporting FDA review after TKI failure.

FDA clears zidesamtinib for previously treated ROS1-positive metastatic NSCLC, showing 44% responses, CNS activity, and manageable safety in ARROS-1 trial.

The NDA for daraxonrasib in PDAC is supported by results from the phase 3 RASolute 302 trial.

Explore second-line options after ICI failure in metastatic ccRCC, featuring TiNivo-2 insights and tivozanib’s tolerability and PFS.

Phase 1/2 SIDNEY interim results show EO2463 boosts CD8 T cells, linking to longer PFS and responses in watch-and-wait patients with indolent NHL.